Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-alpha, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
JOURNAL OF CLINICAL ONCOLOGY(2021)
Key words
simlukafusp alfa,metastatic cervical cancer,atezolizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined